scholarly journals Borderline ovarian tumors

2006 ◽  
Vol 14 (1-2) ◽  
pp. 62-63
Author(s):  
Katarina Mastilovic ◽  
Tatjana Ivkovic-Kapicl ◽  
Milica Zivaljevic ◽  
Jelka Rajovic ◽  
Dejan Nincic
Keyword(s):  
Surgical Treatment ◽  
Malignant Tumors ◽  
Young Patients ◽  
Ovarian Tumors ◽  
Disease Stage ◽  
Early Disease ◽  
Oncogenic Potential ◽  
Stage Of Disease ◽  
Borderline Ovarian Tumors ◽  
Early Disease Stage

Borderline ovarian tumors are classified between benign cystadenoma and malignant cystadenocarcinoma. They are characterized as malignant tumors by histopathological features, which make them different from the benign ones. These tumors are commonly diagnosed at the early disease stage. The treatment of these tumors is surgical. The prognosis depends on the stage of disease and histopahtological types. We present 10 patients operated at the Institute of Oncology Sremska Kamenica because of malignant tumors with low malignant oncogenic potential in the period between 2000 and 2005. All patients had surgical treatment with ex tempore diagnostics, hysterectomy and adnexectomy with total omentectomy, or unilaterals adnexectomy. All patients had negative cytoanalytic findings of the small pelvis. Histopathological findings are necessary to confirm the diagnosis of disease. In young patients who had no children fertility can be preserved.

Colchicine in Behçet Syndrome: A Longterm Survey of Patients in a Controlled Trial

2014 ◽  
Vol 41 (4) ◽  
pp. 735-738 ◽  
Author(s):  
Vedat Hamuryudan ◽  
Gulen Hatemi ◽  
Koray Tascilar ◽  
Sebahattin Yurdakul ◽  
Cem Mat ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Disease Stage ◽  
Early Disease ◽  
Double Blind ◽  
Behçet Syndrome ◽  
Behcet Syndrome ◽  
Cumulative Duration ◽  
Continuous Use ◽  
Early Disease Stage

Objective.To test the hypothesis that colchicine use during early disease decreases immunosuppressive use in Behçet syndrome (BS) in the long term.Methods.Patients with BS who participated in a double-blind, placebo-controlled trial of colchicine 16.6 ± 1.1 years ago were evaluated for immunosuppressive use during the posttrial period.Results.We could contact 90/116 patients; 28 (31%) received immunosuppressives during the posttrial period, 14 being from the colchicine arm. Posttrial colchicine use and cumulative duration were similar between patients who received immunosuppressives and those who did not.Conclusion.Continuous use of colchicine, even when initiated at an early disease stage, does not seem to decrease the use of immunosuppressives in the long term.

scholarly journals Clinical Study of Surgical Combination Chemotherapy in the Treatment of Borderline Ovarian Tumors

1970 ◽  
Vol 1 (1) ◽  
Author(s):  
Chen Ming
Keyword(s):  
Clinical Study ◽  
Surgical Treatment ◽  
Combination Chemotherapy ◽  
Clinical Manifestations ◽  
Research Process ◽  
Clinical Treatment ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumors

Borderline ovarian tumors belong to a kind of epithelial ovarian tumors, nature between benign and malignant, the incidence of ovarian tumors accounted for 4.0% to 14.0%, clinical manifestations and malignant have a greater similarity,will be transferred, and can recurrence[1]. For the disease,most of the clinical treatment will be given, in recent years,after the completion of surgical treatment, our hospital also on such patients with chemotherapy[2]. In this study, 32 patients were divided into two groups, one group received surgery,chemotherapy, a group of patients undergoing surgery alone,the research process and the results reported in the study of the results of the combination of surgery and chemotherapy in the treatment of borderline ovarian tumors as follows.

Sodium Butyrate Reduces Brain Amyloid-β Levels and Improves Cognitive Memory Performance in an Alzheimer’s Disease Transgenic Mouse Model at an Early Disease Stage

2020 ◽  
Vol 74 (1) ◽  
pp. 91-99 ◽  
Author(s):  
W.M.A.D. Binosha Fernando ◽  
Ian J. Martins ◽  
Michael Morici ◽  
Prashant Bharadwaj ◽  
Stephanie R. Rainey-Smith ◽  
...  
Keyword(s):  
Mouse Model ◽  
Transgenic Mouse ◽  
Sodium Butyrate ◽  
Memory Performance ◽  
Amyloid Β ◽  
Transgenic Mouse Model ◽  
Disease Stage ◽  
Early Disease ◽  
Cognitive Memory ◽  
Early Disease Stage

Borderline ovarian tumors: Long-term survival and preservation of fertility.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15508-e15508
Author(s):  
Natasha Gercovich ◽  
Carlos Garcia Gerardi ◽  
Ernesto Gil Deza ◽  
Eduardo L. Morgenfeld ◽  
Edgardo G. J. Rivarola ◽  
...  
Keyword(s):  
Young Patients ◽  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Population Characteristics ◽  
Borderline Tumor ◽  
Term Survival ◽  
Borderline Tumors ◽  
Borderline Ovarian Tumors ◽  
The Usa

e15508 Background: Borderline ovarian tumors, also called low-malignancy potential tumors, are infrequent tumors present predominantly in pre-menopause women. Their evolution after surgical treatment is generally very good. The main objective of this paper is to show the evolution of a group of borderline tumors treated at our institution. Methods: Between January 1, 2000 and January 1, 2010, 36 patients diagnosed with ovarian borderline tumors were examined by two independent pathologists, according to the guidelines established by the USA Association of Directors of Anatomic and Surgical Pathology. These patients were followed at IOHM and comprise this paper’s study group. Results: Population Characteristics: Mean Age: 41 years (Range: 20-85). Affected Ovary (Right: 17 pts; Left: 14 pts; Both: 5 pts). Pathology: Mucinous (17 pts), Serous (16 pts), Clear, Brenner and Endometroid Cells (1 pt each). Stages: IA (24 pts), IB (5 pts), IC (2pts), IIIA (4 pts), IIIC (1 pt). Five patients presented non-invasive peritoneal implants and three presented positive peritoneal liquid. All patients were surgically treated: 28 with total anexohisterectomy (TAH) and 8 with unilateral ooforectomy. No patient was given any chemotherapy or radiotherapy treatment. Four patients did not attend follow-up consultations and were lost after 4, 6, 12 and 29 months with no evidence of disease (NED). Thirty-two patients were followed bi-annually during the first five years and annually thereafter. One patient became pregnant after the surgery. All patients are alive and NED with an average follow up of 50 months (range: 29-133). Conclusions: 1) Although half the cases in the study were under 35 years old, there were 12 tumors present in patients over 50 years of age and 1 borderline tumor present in an 85 year old patient. 2) Surgically treated ovarian borderline tumors have a high chance of being curable without the need of chemotherapy or radiotherapy. 3) Conservative surgery in young patients allows a conservation of fertility, provided they are subject to an adequate follow-up.

Outcomes of Innovative Programmed Treatment of Children with Malignant Loco-Motor System Tumors in Moscow

2013 ◽  
Vol 20 (1) ◽  
pp. 52-57
Author(s):  
A. V Shvarova ◽  
L. D Volkova ◽  
A. A Ochkurenko ◽  
N. V Ivanova
Keyword(s):  
Surgical Treatment ◽  
Survival Rate ◽  
Treatment Program ◽  
Motor System ◽  
Malignant Tumors ◽  
Stage Of Disease ◽  
Moscow City

During the period from 2005 to 2010 forty nine patients from Moscow city aged 1 — 16 years (mean age 9.4 years) were treated for malignant tumors (MT) of loco-motor system. Localized process was diagnosed in 25 (51%) patients, IV stage of disease in 24 (49%) children. Use of adopted treatment program including intensive polychemotherapy, organ-saving surgical treatment and radiotherapy enabled to achieve optimistic results. Overall 2-years survival rate for children with loco-motor system MT made up 64.3±7.2%, i.e. 86.5±7.2% in localized and 42.6±10.5% in disseminated process.

Fertility-Sparing Surgery for Borderline Ovarian Tumors: Oncologic Safety and Reproductive Outcomes

2011 ◽  
Vol 21 (4) ◽  
pp. 640-646 ◽  
Author(s):  
Taejong Song ◽  
Chel Hun Choi ◽  
Hwang Shin Park ◽  
Min-Kyu Kim ◽  
Yoo-Young Lee ◽  
...  
Keyword(s):  
Young Patients ◽  
Ovarian Tumors ◽  
Reproductive Outcomes ◽  
Recurrence Rates ◽  
Main Site ◽  
Oncological Safety ◽  
Borderline Ovarian Tumors ◽  
Fertility Sparing Surgery ◽  
Initial Surgery ◽  
Fertility Sparing

Introduction:To evaluate the oncological safety and reproductive outcomes of patients with borderline ovarian tumors (BOTs) treated with fertility-sparing surgery.Methods:Patients with BOTs who underwent radical or fertility-sparing surgery between 1997 and 2009 were identified from an institutional database. The recurrence rates were compared between the 2 surgery groups. To compare the reproductive outcomes, all patients who underwent fertility-sparing surgery were interviewed by telephone.Results:One hundred forty-three patients underwent radical surgery, and 155 patients underwent fertility-sparing surgery. After a median interval of 38 months from the initial surgery (range, 10-77 months), 19 patients had a recurrence. The recurrence rate was similar in the radical and fertility-sparing surgery groups (4.9% and 7.7%, respectively;P= 0.280). In the fertility-sparing surgery group, however, the main site of recurrence was the remaining ovary that was successfully salvaged with a second round of fertility-sparing surgery. Of 51 patients who attempted to conceive, 45 patients (88.2%) were successful and resulted in 54 term deliveries.Conclusions:Fertility-sparing surgery for BOTs is safe and can result in future pregnancies, suggesting that such surgery should be considered for young patients who desire preservation of fertility.

Sign in / Sign up

Export Citation Format

Share Document